Skip to content
Biodatica
Start free

AstraZeneca

Beijing

OncologyantibodyPhase IIIListed · AZN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Clinical Trial of Minimally Invasive Surgery Versus Abdominal Surgery in Patients With Early Stage Cervical Cancer

6mo agoTrial registeredDec 31, 2025Source filing (opens the source filing in a new tab)

Momentum

62no change

Momentum 62 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Dec 1, 2020

    Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer · ACTIVE_NOT_RECRUITING · sponsor: Huazhong University of Science and Technology · Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

    ClinicalTrials.gov · NCT04516616 (opens the source filing in a new tab)

  2. Trial

    NA registered

    May 1, 2019

    Uterine Cervical Neoplasm · ACTIVE_NOT_RECRUITING · sponsor: Huazhong University of Science and Technology · Clinical Trial of Minimally Invasive Surgery Versus Abdominal Surgery in Patients With Early Stage Cervical Cancer

    ClinicalTrials.gov · NCT03955185 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    May 29, 2018

    Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive · COMPLETED · sponsor: AstraZeneca · Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

    ClinicalTrials.gov · NCT03534453 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources